No label defined (Q32050)
Jump to navigation
Jump to search
No description defined
- Effects of gender-affirming hormone therapy on gray matter density, microstructure and monoamine oxidase A levels in transgender subjects.
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | No label defined |
No description defined |
|
Statements
MAO-A catalyzes the oxidative degradation of monoamines and is thus implicated in sex-specific neuroplastic processes that influence gray matter (GM) density (GMD) and microstructure (GMM). (English)
Copyright © 2024. Published by Elsevier Inc. (English)
2024
Given the exact monitoring of plasma hormone levels and sex steroid intake, transgender individuals undergoing gender-affirming hormone therapy (GHT) represent a valuable cohort to potentially investigate sex steroid-induced changes of GM and concomitant MAO-A density. (English)
Copyright © 2024. Published by Elsevier Inc. (English)
2024
Here, we investigated the effects of GHT over a median time period of 4.5 months on GMD and GMM as well as MAO-A distribution volume. (English)
Copyright © 2024. Published by Elsevier Inc. (English)
2024
To this end, 20 cisgender women, 11 cisgender men, 20 transgender women and 10 transgender men underwent two MRI scans in a longitudinal design. (English)
Copyright © 2024. Published by Elsevier Inc. (English)
2024
PET scans using [<sup>11</sup>C]harmine were performed before each MRI session in a subset of 35 individuals. (English)
Copyright © 2024. Published by Elsevier Inc. (English)
2024
GM changes determined by diffusion weighted imaging (DWI) metrics for GMM and voxel based morphometry (VBM) for GMD were estimated using repeated measures ANOVA. (English)
Copyright © 2024. Published by Elsevier Inc. (English)
2024
Regions showing significant changes of both GMM and GMD were used for the subsequent analysis of MAO-A density. (English)
Copyright © 2024. Published by Elsevier Inc. (English)
2024
These involved the fusiform gyrus, rolandic operculum, inferior occipital cortex, middle and anterior cingulum, bilateral insula, cerebellum and the lingual gyrus (post-hoc tests: p<sub>FWE+Bonferroni</sub> < 0.025). (English)
Copyright © 2024. Published by Elsevier Inc. (English)
2024
In terms of MAO-A distribution volume, no significant effects were found. (English)
Copyright © 2024. Published by Elsevier Inc. (English)
2024
Additionally, the sexual desire inventory (SDI) was applied to assess GHT-induced changes in sexual desire, showing an increase of SDI scores among transgender men. (English)
Copyright © 2024. Published by Elsevier Inc. (English)
2024
Changes in the GMD of the bilateral insula showed a moderate correlation to SDI scores (rho = - 0.62, p<sub>Bonferroni</sub> = 0.047). (English)
Copyright © 2024. Published by Elsevier Inc. (English)
2024
The present results are indicative of a reliable influence of gender-affirming hormone therapy on 1) GMD and GMM following an interregional pattern and 2) sexual desire specifically among transgender men. (English)
Copyright © 2024. Published by Elsevier Inc. (English)
2024
P A (English)
Handschuh (English)
PA
M B (English)
Reed (English)
MB
M (English)
Murgaš (English)
M
U (English)
Kaufmann (English)
U
M (English)
Klöbl (English)
M
M E (English)
Konadu (English)
ME
B (English)
Spurny-Dworak (English)
B
A (English)
Hahn (English)
A
M (English)
Spies (English)
M
P (English)
Baldinger-Melich (English)
P
R (English)
Lanzenberger (English)
R
12 August 2024
12 August 2024
Declaration of competing interest With relevance to this work there is no conflict of interest to declare. (English)
R. Lanzenberger received travel grants and/or conference speaker honoraria within the last three years from Bruker BioSpin MR, Heel, and support from Siemens Healthcare regarding clinical research using PET/MR. (English)
He is a shareholder of the start-up company BM Health GmbH since 2019. (English)
Kranz declares that he received conference speaker honorarium from Roche, AOP Orphan and Pfizer. (English)
P. Handschuh received authorship honoraria from MedMedia Verlag and a travel grant from Angelini Pharma. (English)
The other authors report no conflict of interest. (English)